DE60140285D1 - Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts - Google Patents

Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts

Info

Publication number
DE60140285D1
DE60140285D1 DE60140285T DE60140285T DE60140285D1 DE 60140285 D1 DE60140285 D1 DE 60140285D1 DE 60140285 T DE60140285 T DE 60140285T DE 60140285 T DE60140285 T DE 60140285T DE 60140285 D1 DE60140285 D1 DE 60140285D1
Authority
DE
Germany
Prior art keywords
growth hormone
mobility
promote
digestive tract
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140285T
Other languages
English (en)
Inventor
John Hakkinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60140285D1 publication Critical patent/DE60140285D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
DE60140285T 2000-05-31 2001-05-16 Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts Expired - Lifetime DE60140285D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20823400P 2000-05-31 2000-05-31

Publications (1)

Publication Number Publication Date
DE60140285D1 true DE60140285D1 (de) 2009-12-10

Family

ID=22773794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140285T Expired - Lifetime DE60140285D1 (de) 2000-05-31 2001-05-16 Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts

Country Status (14)

Country Link
US (2) US6548501B2 (de)
EP (1) EP1159964B1 (de)
JP (4) JP3842987B2 (de)
KR (1) KR20010109139A (de)
AT (1) ATE446758T1 (de)
AU (1) AU4811401A (de)
CA (1) CA2349142C (de)
DE (1) DE60140285D1 (de)
ES (1) ES2333097T3 (de)
HU (1) HUP0102272A3 (de)
IL (1) IL143388A0 (de)
MY (1) MY134190A (de)
NZ (1) NZ512072A (de)
ZA (1) ZA200104396B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6494888B1 (en) * 1999-06-22 2002-12-17 Ndo Surgical, Inc. Tissue reconfiguration
US6663639B1 (en) 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US6835200B2 (en) * 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US8287554B2 (en) * 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
EP1149583A3 (de) * 2000-04-13 2001-11-14 Pfizer Products Inc. Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern
ATE446758T1 (de) * 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
EP1312363A1 (de) * 2001-09-28 2003-05-21 Pfizer Products Inc. Behandlungsverfahren und kits bestehend aus Wachstumshormonsekretionsförderern
US20090198050A1 (en) * 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
WO2004111077A1 (en) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US20060204436A1 (en) * 2003-06-25 2006-09-14 Cornelia Hertel Tritiated growth hormone secretagogue mk-0677
EP2316846B1 (de) * 2003-07-31 2019-10-02 Ocera Therapeutics, Inc. Räumlich definierte makrozyklische Verbindungen zur Entdeckung von Arzneimitteln
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
IL158658A0 (en) * 2003-10-29 2004-05-12 Moshe Schwarzberg Prokinetic drugs assistance to small intestine imaging
CA2565324A1 (en) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
US8129359B2 (en) 2004-06-04 2012-03-06 Ethicon, Inc. Composition and method for treating post-surgical pain
US20070141156A1 (en) * 2005-12-21 2007-06-21 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
US8377906B2 (en) * 2004-06-04 2013-02-19 Ethicon, Inc. Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
US7381728B2 (en) 2004-07-28 2008-06-03 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
KR20130048793A (ko) 2004-08-12 2013-05-10 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을 촉진하는 방법
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
AU2005277389A1 (en) * 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
WO2007014258A2 (en) * 2005-07-22 2007-02-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Growth hormone secretagogues
PT1937262T (pt) * 2005-09-29 2019-08-21 Ipsen Pharma Sas Composição para utilização no tratamento de dismotilidade gastrointestinal
US7576606B2 (en) * 2007-07-25 2009-08-18 D2Audio Corporation Digital PWM amplifier having a low delay corrector
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
TW200808709A (en) 2006-03-31 2008-02-16 Glaxo Group Ltd Novel compounds
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2118080B1 (de) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Makrocyclische ghrelin-rezeptormodulatoren und verwendungsverfahren dafür
AU2008216789A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
US20080234703A1 (en) * 2007-03-23 2008-09-25 Ethicon Endo-Surgery, Inc. Tissue approximation system
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US7728658B2 (en) * 2007-07-25 2010-06-01 D2Audio Corporation Low-noise, low-distortion digital PWM amplifier
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
WO2009082426A1 (en) * 2007-12-21 2009-07-02 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
CA2735177C (en) * 2008-08-29 2014-03-25 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Saturated bicyclic heterocyclic derivatives as smo antagonists
KR100991032B1 (ko) * 2008-12-08 2010-10-29 삼일제약주식회사 위장관 운동 조절용 약학 조성물
CN102762564B (zh) * 2010-02-26 2015-09-30 拉夸里亚创药株式会社 用于治疗恶病质的葛瑞林受体激动剂
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8546416B2 (en) * 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
ES2959427T3 (es) 2012-09-27 2024-02-26 Elanco Animal Health Incorporated Composiciones farmacéuticas para el tratamiento de la inapetencia
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
JP6299683B2 (ja) 2015-06-25 2018-03-28 トヨタ自動車株式会社 燃料電池システム
DK3352752T3 (da) * 2015-09-21 2022-02-28 Lumos Pharma Inc Påvisning og behandling af væksthormonmangel

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
EP0400051B1 (de) 1988-01-28 1995-05-10 Polygen Holding Corporation Polypeptide mit hormonwachstumsbefreiender wirkung
ATE113607T1 (de) 1988-01-28 1994-11-15 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
EP0669830A4 (de) 1992-11-06 1997-02-26 Merck & Co Inc Substituierte dipeptidanaloge, welche die freisetzung von wachstumshormon unterstützen.
US5726319A (en) 1992-11-06 1998-03-10 Merck & Co., Inc. Biphenyl substituted dipeptide analogs promote release of growth hormone
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
HUT72076A (en) 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
PL314003A1 (en) 1993-10-19 1996-08-05 Merck & Co Inc Combination of bisulphonates and substances enhancing secretion of growth hormone
EP0739204A4 (de) 1993-11-09 2000-03-15 Merck & Co Inc Piperidine, pyrrolidine und hexahydro-1h-azepine unterstützen die freisetzung des wachstumshormon
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
WO1995014666A1 (en) 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
SK281963B6 (sk) 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
CA2179598A1 (en) 1993-12-23 1995-06-29 Nils Langeland Johansen Compounds with growth hormone releasing properties
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
US5783582A (en) 1994-07-20 1998-07-21 Merck & Co., Inc. Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO1996022996A1 (fr) 1995-01-25 1996-08-01 Nippon Chemiphar Co., Ltd. Derives de dihydrophenazine
ID18218A (id) 1995-01-27 1998-03-19 Novo Nordisk As Senyawa dengan sifat-sifat pelepas hormon pertumbuhan
AU4534696A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5559128A (en) 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
EP0823904A4 (de) 1995-04-19 1998-09-09 Merck & Co Inc Verfahren zur herstellung von spiroindolinen
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
MX9709278A (es) 1995-05-29 1998-03-31 Pfizer Dipeptidos que promueven la liberacion de la hormona de crecimiento, composiciones que los contienen y uso de los mismos.
HUP9802821A3 (en) 1995-06-22 2000-03-28 Novo Nordisk As Compounds with growth hormone releasing properties
WO1997007117A1 (en) 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamines as growth hormone secretagogues
WO1997006803A1 (en) 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
AU7169696A (en) 1995-09-26 1997-04-17 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
KR19990067097A (ko) 1995-10-27 1999-08-16 폴락 돈나 엘. 성장 호르몬 분비 촉진제의 제조 방법
EP0876402B1 (de) 1995-12-13 2004-10-13 Merck & Co., Inc. Wachstumshormonsekretionsförderer rezeptorfamilie
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
IT1277113B1 (it) 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
WO1997022367A1 (en) 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue
ES2323159T3 (es) 1995-12-22 2009-07-07 Novo Nordisk A/S Compuestos con propiedades de liberacion de la hormona del crecimiento.
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1997034604A1 (en) 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
AU2722297A (en) 1996-04-03 1997-10-22 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
SE9601397D0 (sv) 1996-04-12 1996-04-12 Pharmacia Ab Use of growth hormone
WO1997040071A1 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2252761A1 (en) 1996-04-24 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5919777A (en) 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1997041878A1 (en) 1996-05-07 1997-11-13 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
EP0912551A1 (de) 1996-05-14 1999-05-06 Novo Nordisk A/S Somatostatin-agonisten und -antagonisten
US6071926A (en) 1996-05-22 2000-06-06 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
HUP9904049A3 (en) 1996-05-31 2000-07-28 Novo Nordisk As Growth hormone component and bone anti-resorptive agent in cyclic(coherence)treatment of osteoporosis
EP0923539B1 (de) 1996-07-22 2002-06-05 Novo Nordisk A/S Verbindungen mit wachstumshormon freisetzenden eigenschaften
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998046569A1 (fr) 1997-04-11 1998-10-22 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzene
JP2000514838A (ja) 1997-05-14 2000-11-07 藤沢薬品工業株式会社 成長ホルモンの放出を促進するピペリジノ誘導体
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
DE69837264T2 (de) 1997-06-25 2008-01-31 Pfizer Inc. Dipeptidverbindungen, die Wachstumshormon-Sekretagoga sind
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
AU758160B2 (en) 1997-08-22 2003-03-20 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
CA2377721A1 (en) * 1999-06-30 2001-01-04 Zymogenetics, Inc. Sgip peptides
AU6497701A (en) * 2000-05-30 2001-12-11 Merck & Co Inc Melanocortin receptor agonists
ATE446758T1 (de) * 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts

Also Published As

Publication number Publication date
US20020042419A1 (en) 2002-04-11
JP2013139482A (ja) 2013-07-18
EP1159964A2 (de) 2001-12-05
NZ512072A (en) 2002-10-25
US6548501B2 (en) 2003-04-15
MY134190A (en) 2007-11-30
CA2349142C (en) 2005-07-12
EP1159964B1 (de) 2009-10-28
JP2006265270A (ja) 2006-10-05
KR20010109139A (ko) 2001-12-08
ATE446758T1 (de) 2009-11-15
JP3842987B2 (ja) 2006-11-08
US20030225096A1 (en) 2003-12-04
HU0102272D0 (en) 2001-08-28
US6852722B2 (en) 2005-02-08
AU4811401A (en) 2001-12-06
ES2333097T3 (es) 2010-02-17
IL143388A0 (en) 2002-04-21
HUP0102272A3 (en) 2003-09-29
EP1159964A3 (de) 2003-10-01
CA2349142A1 (en) 2001-11-30
HUP0102272A2 (hu) 2002-02-28
ZA200104396B (en) 2002-11-29
JP2015127344A (ja) 2015-07-09
JP2002012556A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
DE60140285D1 (de) Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
MXPA04005906A (es) Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
AU2134402A (en) Antiviral agents
TNSN04165A1 (en) Substituted hydroxyethylamines
IL154536A0 (en) Immunoregulatory compounds and derivatives and methods of treating diseases therewith
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
WO2004056365A3 (en) Derivatives of aryl-quinazoline/aryl-2amino-phenyl methanone which promote the release of parathyroid hormone
EP1175900A3 (de) Verwendung von Sekretionsfördermittel für Wachstumshormone zu Verbesserung des funktionellen Gesundheitsstatus
EP1184035A3 (de) Verwendung von Sekretionsfördermitteln für Wachstumshormone zu Behandlung des physischen Leistungsabbaus
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
MXPA03011626A (es) Derivados de quinazolina que promueven la liberacion de hormona paratiroides.
HK1075894A1 (en) Prucalopride-n-oxide
PL377478A1 (pl) Cykloalkenowe kwasy dikarboksylowe jako środki przeciwzapalne, immunomodulujące oraz antyproliferacyjne
EP1181933A3 (de) Verwendung von wachstumshormonsekretion-fördernden mitteln zur appetit erholung
ATE292110T1 (de) Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit
EP1192943A3 (de) Verwendung von Sekretionsfördermitteln für Wachstumshormone in Verbindung mit Körpertraining
WO2002058680A3 (en) Use of bicylic amino acids for preventing and treating visceral pain and gastrointestinal disorders
DE602004030265D1 (de) Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
ATE301997T1 (de) Antivirale therapie
TW200509917A (en) Use of growth hormone secretagogues for treatment of fibromyalgia
IL143873A0 (en) Dry skin remedies
ATE270886T1 (de) Antivirale therapie
RU2000122595A (ru) Лекарственное средство для лечения пиелонефрита

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: RAQUALIA PHARMA INC., AICHI-KEN, JP

8364 No opposition during term of opposition